Unlocking the Undruggable Proteome
With the Worlds First AI-Powered Trillion-Molecule Screening
Harnessing AI and Synthetic Biology to explore the Yotta Scale Design Space
Nearly half of the human proteome remains inaccessible for traditional drug discovery, largely due to intrinsically disordered regions and the limitations of current protein structure models, which are trained on just a fraction of available data.
At Aikium, we are redefining what’s possible for protein therapeutics by integrating deep learning with ultra-large-scale wet lab experimentation — enabling the pioneering development of next-generation drugs that can access and treat the “undruggable” half of the human proteome.
The Industry’s Pioneering Platform: Creation of the Next-Generation Protein Therapeutics
Founded by visionary leaders from NVIDIA, Harvard, 10x Genomics, NIH, and the Wyss Institute, our team is pioneering a new era in drug discovery. We leverage advanced AI to design and screen Yotta-scale wet-lab libraries with unprecedented precision and scalability.
Our platform targets the most challenging regions of disease associated hard-to-treat targets — including GPCRs and ion channels — where traditional antibodies and small molecules fall short. With unmatched depth and accuracy, we are unlocking new therapeutic possibilities for previously intractable conditions.
Investors
Join our visionary founding team and help build a groundbreaking platform poised to revolutionize the future of medicine
Together, we’re on a mission to deliver 100 life-changing therapies in the next decade — reshaping what’s possible for patients worldwide.
